Genmab

PO Box 9068
Copenhagen K
1260
Denmark

+45 70 20 27 28

Activities

Ingredients | R and D

Related Content

Genmab chooses Ibex to take gene candidates to IND in 12 months

Personalised cancer treatment 2.0: new combination strategy developed

Tisotumab Vedotin co-developed by Genmab and Seattle Genetics

Genmab enters licensing agreement with Gilead for DuoBody technology

Novo Nordisk pays US$2m for access to Genmab technology

Genmab teams up with BioNTech in immuno-oncology development and commercialisation agreement

Multiple myeloma – daratumumab

Seattle Genetics and Genmab enter into new antibody-drug conjugate collaboration

Genmab unveils novel platform to enhance antibody therapeutics

Genmab licenses HuMax-IL8 to Cormorant Pharmaceuticals

Jobs and People

Genmab appoints new CDO

Similar Companies